Defining risk status in the first-line treatment of metastatic renal cell carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 7, 2010, Pages 961-968

  Schmidinger, Manuela ^a   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Memorial Sloan Kettering Cancer Center model; Metastatic renal cell carcinoma; Risk factors; Sunitinib; Targeted agents

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WOUND HEALING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 77953229828     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0901-0     Document Type: Review

References (39)

1. N Bhojani C Jeldres JJ Patard, et al. 2008 Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma Eur Urol 53 917 930 10.1016/j.eururo.2007.11.037 1:CAS:528:DC%2BD1cXns1ejsbc%3D 18054825
2. Coppin C, Porzsolt F, Awa A et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1):CD001425
3. Dutcher JP, Szczylik C, Tannir N et al (2007) Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25(18S Part 1):243 s (Abstract 5033)
4. Escudier B, Koralewski P, Pluzanska A et al (2007a) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon- α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25(18S Part 1):2 s (Abstract 3)
5. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 17215530 (Pubitemid 46089673)
6. B Escudier A Pluzanska P Koralewski, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 10.1016/S0140-6736(07)61904-7 18156031 (Pubitemid 350296300)
7. Escudier BJ, Bellmunt J, Negrier S et al (2009) Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastaric renal cell carcinoma (mRCC). J Clin Oncol 27:Abstr 5020 (Oral presentation)
8. J Ferlay P Autier M Boniol, et al. 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581 592 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242 (Pubitemid 46359643)
9. ME Gore C Szczylik C Porta, et al. 2009 Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma Lancet Oncol 10 757 763 10.1016/S1470-2045(09)70162-7 1:CAS:528:DC%2BD1MXptlalsrc%3D 19615940
10. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: results from a large multicenter study. J Clin Oncol 27 5 s (suppl; abstr 5041)
11. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D 17538086 (Pubitemid 46849157)
12. NK Janzen HL Kim RA Figlin, et al. 2003 Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 843 852 10.1016/S0094-0143(03)00056-9 14680319 (Pubitemid 37485197)
13. W Lilleby SD Fossa 2005 Chemotherapy in metastatic renal cell cancer World J Urol 23 175 179 10.1007/s00345-004-0469-x 1:CAS:528:DC%2BD2MXmsFWmtbw%3D 15726382 (Pubitemid 41136038)
14. Ljungberg B, Hanbury DC, Kuczyk MA et al (2009) Guidelines on renal cell carcinoma (2009). European Association of Urology http://www.uroweb.org/ fileadmin/tx-eauguidelines/2009/Full/RCC.pdf
15. RJ Motzer NH Bander DM Nanus 1996 Renal-cell carcinoma N Engl J Med 335 865 875 10.1056/NEJM199609193351207 1:STN:280:DyaK28zlslajtA%3D%3D 8778606 (Pubitemid 26304070)
16. RJ Motzer J Bacik BA Murphy, et al. 2002 Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 289 296 10.1200/JCO.20.1.289 1:CAS:528: DC%2BD38XnsFeqtg%3D%3D 11773181 (Pubitemid 34032623)
17. Motzer RJ, Figlin R, Hutson TE et al (2007a) Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Oral presentation at the Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 1-5, 2007 (Abstract 5024)
18. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529 (Pubitemid 46089672)
19. Motzer RJ, Michaelson MD, Hutson TE et al (2007c) Sunitinib versus interferon-alfa (IFN-á) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. Poster presentation at: the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007
20. RJ Motzer RM Bukowski RA Figlin, et al. 2008 Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 1552 1558 10.1002/cncr.23776 1:CAS:528:DC%2BD1cXht1Ggu7bO 18720362
21. RJ Motzer B Escudier S Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D 18653228
22. RJ Motzer TE Hutson P Tomczak, et al. 2009 Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma J Clin Oncol 27 3584 3590 10.1200/JCO.2008.20.1293 1:CAS:528:DC%2BD1MXhtVOnu7nI 19487381
23. National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: kidney cancer v.2.2010. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
24. DM Parkin F Bray J Ferlay, et al. 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
25. Patil S, Ishill NM, Deluca J et al (2008) Trends in memorial Sloan-Kettering cancer center risk group distribution according to treatment year for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 (May 20 suppl):(Abstract 5092)
26. Pfizer Inc (2009a) SUTENT, Summary of product characteristics, October 2009
27. Pfizer Inc (2009b) Torisel, Summary of product characteristics. September 2009
28. C Porta C Szczylik 2009 Tolerability of first-line therapy for metastatic renal cell carcinoma Cancer Treat Rev 35 297 307 10.1016/j.ctrv.2008.12.003 1:CAS:528:DC%2BD1MXksVant74%3D 19249157
29. C Porta J Bellmunt T Eisen, et al. 2010 Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma Cancer Treat Rev 36 16 23 10.1016/j.ctrv.2009.09.001 19819078
30. RA Rabinovitch MJ Zelefsky JJ Gaynor, et al. 1994 Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy J Clin Oncol 12 206 212 1:STN:280: DyaK2c%2Fps1Smug%3D%3D 8270978
31. A Ravaud 2009 How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents Ann Oncol 20 Supplement 1 i7 i12 10.1093/annonc/mdp073 19430007
32. BI Rini I Tamaskar P Shaheen, et al. 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 99 81 83 1:CAS:528:DC%2BD2sXhs1Wnur4%3D 17202116
33. Rini BI, Halabi S, Rosenberg JE et al (2008) CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Oral presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, California, USA, February 14-16, 2008
34. BI Rini S Halabi JE Rosenberg, et al. 2008 Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 5422 5428 10.1200/JCO.2008.16.9847 1:CAS:528:DC%2BD1MXhslClsA%3D%3D 18936475
35. Rini BI, Halabi S, Rosenberg J et al (2009) Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 27:Abstr LBA5019 (oral presentation)
36. ® (bevacizumab). Summary of product characteristics. August 2009
37. M Schmidinger CC Zielinski UM Vogl, et al. 2008 Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 5204 5212 10.1200/JCO.2007.15.6331 18838713
38. WM Stadler RA Figlin DF McDermott, et al. 2010 Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 1272 1280 10.1002/cncr.24864 1:CAS:528: DC%2BC3cXjs1GrtLg%3D 20082451
39. CN Sternberg ID Davis J Mardiak, et al. 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 1061 1068 10.1200/JCO.2009.23.9764 1:CAS:528: DC%2BC3cXktF2lt78%3D 20100962